University Department of Surgery, Faculty of Medicine, Royal Infirmary, University of Glasgow, Glasgow, Scotland, UK.
Ann Surg Oncol. 2011 Sep;18(9):2604-12. doi: 10.1245/s10434-011-1658-7. Epub 2011 Mar 16.
A number of accepted criteria, including pathological tumor, node, metastasis system stage, lymph node metastasis, and tumor differentiation, predict survival in patients undergoing surgery for gastroesophageal cancer. We examined the interrelationships between standard clinicopathological factors, systemic and local inflammatory responses, tumor proliferative activity, and survival.
The interrelationships between the systemic inflammatory response (Glasgow prognostic score, mGPS), standard clinicopathological factors, local inflammatory response (Klintrup criteria, macrophage infiltration), and tumor proliferative activity (Ki-67) were examined by immunohistochemistry in 100 patients (44 esophageal [19 squamous, 25 adenocarcinoma], 19 junctional, and 37 gastric cancers) selected for potentially curative resection.
The minimum follow-up was 59 months. On multivariate survival analysis, lymph node ratio (hazard ratio [HR] 1.63, 95% confidence interval [CI] 1.11-2.40, P < 0.05), tumor differentiation (HR 2.63, 95% CI 1.45-4.77, P = 0.001), mGPS (HR 3.91, 95% CI 1.96-8.11, P < 0.001), Klintrup score (HR 3.47, 95% CI 1.14-10.55, P < 0.05), and Ki-67 (HR 0.67, 95% CI 0.47-0.96, P < 0.05) were independently associated with cancer-specific survival. A higher lymph node ratio was associated with poor tumor differentiation (P < 0.05), low-grade Klintrup criteria (P < 0.005), and low tumor proliferative activity (P < 0.05).
Tumor proliferation rate and local and systemic inflammatory responses are important predictors of survival, albeit in a heterogeneous cohort of patients including esophageal, junctional, and gastric cancers. These scores may be combined with accepted tumor-based factors to improve prediction of outcome.
包括病理肿瘤、淋巴结、转移系统分期、淋巴结转移和肿瘤分化在内的一些公认标准可预测接受胃食管癌症手术治疗的患者的生存情况。我们检查了标准临床病理因素、全身和局部炎症反应、肿瘤增殖活性之间的相互关系,并与生存情况进行了比较。
通过免疫组织化学检测,对 100 例(44 例食管[19 例鳞癌,25 例腺癌]、19 例交界处和 37 例胃癌)潜在可治愈性切除的患者进行全身炎症反应(格拉斯哥预后评分,mGPS)、标准临床病理因素、局部炎症反应(克林特鲁普标准,巨噬细胞浸润)和肿瘤增殖活性(Ki-67)之间的相互关系。
最小随访时间为 59 个月。多变量生存分析显示,淋巴结比率(危险比[HR]1.63,95%置信区间[CI]1.11-2.40,P<0.05)、肿瘤分化(HR 2.63,95%CI1.45-4.77,P=0.001)、mGPS(HR 3.91,95%CI1.96-8.11,P<0.001)、克林特鲁普评分(HR 3.47,95%CI1.14-10.55,P<0.05)和 Ki-67(HR 0.67,95%CI0.47-0.96,P<0.05)独立与癌症特异性生存相关。较高的淋巴结比率与肿瘤分化不良(P<0.05)、低级别克林特鲁普标准(P<0.005)和肿瘤增殖活性低(P<0.05)相关。
肿瘤增殖率和局部及全身炎症反应是生存的重要预测指标,尽管纳入了包括食管、交界处和胃癌在内的异质性患者队列。这些评分可能与公认的肿瘤相关因素相结合,以提高预后预测的准确性。